Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.23 HKD | +1.95% | 0.00% | -21.23% |
May. 02 | Alphamab Oncology's 2023 Loss Narrows as Revenue Rises | MT |
Apr. 10 | Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.23% | 629M | - | ||
+17.96% | 44.96B | B- | ||
+1.17% | 42.65B | B | ||
+48.77% | 41.85B | A | ||
-4.27% | 29.04B | C | ||
+11.42% | 26.08B | B- | ||
-21.39% | 19.03B | B | ||
+4.86% | 12.75B | B+ | ||
+27.29% | 12.06B | C+ | ||
-3.50% | 11.75B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 9966 Stock
- Ratings Alphamab Oncology